We also examined the effect of GZ17-6.02 on recently identified glioblastoma super-enhancer genes WSCD1, EVOL2, and KLHDC8A as well as the enzyme FADS2, which mediates ELOVL2 signaling [8]. The gene discussed is ELOVL2; the disease is glioblastoma.